CATALYSIS Advises Microdialysis Pioneer Dipylon Medical AB on the Sale of its Clinical Microdialysis Assets to M dialysis AB

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Dipylon Medical AB on the sale of its clinical microdialysis assets and wholly-owned subsidiary in the United States to M Dialysis AB.  Financial terms were not disclosed.

Dipylon Medical AB (Solna, Sweden) is a privately held manufacturer of microdialysis products. Founded in 1984, the company pioneered the microdialysis technique for in vivo sampling and monitoring of organs and tissues. In July 2011, Dipylon announced the sale of its pre-clinical microdialysis business unit as well as the name CMA Microdialysis to Harvard Bioscience, Inc. In August 2011, Dipylon announced the sale of DiLab (an automated blood sampling business) to VeruTech AB.  For more information, visit

M Dialysis AB (Solna, Sweden and Boston, MA, United States) provides market leading tissue microdialysis solutions to clinicians and researchers to enable optimized patient care and accelerated drug development. M Dialysis’s complete line of clinical products, including instruments, consumables and computer software are used globally by universities and hospitals. For more information, visit

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.